LONDON (ShareCast) - (Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has seen a less than ideal response to its recent Phase III Interest trial of its acute respiratory distress syndrome treatment, with early analysis suggesting the product had not performed as expected.
Early analysis of certain biomarker indicators has suggested that Faron's ARDS treatment, Traumakine, had not produced the anticipated interferon-beta bioactivity in the treatment group as previously seen in its Phase I/II.

"It is still too early to understand why this is the case," Faron said on Friday, citing a number of possible causes including, inter alia, formulation, administration and deactivation.

"Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis," the firm added.

AS of 0850 BST, Faron shares had gained 2.84% to 156.83p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE